Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + dacarbazine + interferon alfa-2a as first-line therapy in metastatic melanoma
2005-001316-47Phase 2Completed
- Sponsor
- Turku University Hospital
- Start
- Apr 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in melanoma, sponsored by Turku University Hospital. Primary endpoints: Tumor response rate (RECIST), Progression-free survival and 4 more. Started Apr 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-001316-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001316-47.